How can regular exercise be integrated into the patient journey?
Although the benefits of exercise in patients with cancer are now well established, barriers to an effective integration of physical activity into cancer care remain
The long road toward treatment personalisation for pancreatic and rectal cancers
The 2025 ESMO Awardee, Thierry Conroy, traces the major advances in the field while noting that several barriers to improving patient outcomes remain
ctDNA testing may help refine surveillance strategy for colorectal cancer
Study findings show that ctDNA is a stronger biomarker than carcinoembryonic antigen to select patients who may benefit from metastasis-directed therapy
Promising activity reported for olaparib in advanced biliary tract cancers
Study indicates that PARP inhibition could extend treatment options for patients with biliary tract cancers
Prolonged intertreatment interval improves outcomes to EGFR rechallenge in metastatic colorectal cancer
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed
ctDNA and RNA-based tests are expanding colorectal cancer screening options
The availability of simpler, less-invasive methodologies may help to encourage participation in secondary prevention programmes
Atezolizumab and bevacizumab after transarterial chemoembolisation prolongs progression-free survival in unresectable hepatocellular carcinoma
Data from the TALENTACE trial add to growing evidence supporting the combination of immunotherapy plus anti-VEGF component with TACE
Decoding genomic and transcriptomic signatures in colorectal cancer – next steps?
Newer technologies build on current knowledge to provide greater insights in the molecular landscape
Combinations show promise in hepatocellular carcinoma populations with poor prognosis
Encouraging data were presented for FGF19-positive tumours and those with worse hepatic function, performance status or advanced vascular invasion
Givastomig combined with immunochemotherapy shows clinical activity in metastatic gastro-oesophageal adenocarcinomas
Preliminary results revealed that the combination of claudin 18.2/4-1BB bispecific antibody with nivolumab and mFOLFOX was also well tolerated